IPO Outlook: 2021 Saw Record Numbers But Poor Returns; 2022 Looks Muted
Number Of 2021 Offerings Exceeded 2020, But Returns Faltered
Executive Summary
Initial public offering momentum decelerated as stock prices declined last year, but even with lower valuations making M&A more attractive, the IPO market this year is expected to be active.
You may also be interested in...
US IPO Market In 2022 Even Underperformed Normal Years
INFOGRAPHIC: The number of biopharma offerings in 2022 was far below records set in 2020 and 2021, but also below more normal years of 2018 and 2019. The IPO class of 2022 eked out a positive average return, however.
Finance Watch: VC Round Extensions Attractive While Stock Market Wobbles
Private Company Edition: While Coya Therapeutics raised $15.25m in the final initial public offering in the US last year, Apnimed stayed private raising $80m in a series C extension and Metagenomi extended its series B by $100m to total $275m.
Outlook 2023: The Pharma Rollercoaster Shows No Signs Of Slowing Down
What will 2023 bring as the industry faces one of the toughest periods in the last decade? In Vivo asked three industry experts for their views.